Defining and listing very rare cancers of paediatric age: consensus of the Joint Action on Rare Cancers in cooperation with the European Cooperative Study Group for Pediatric Rare Tumors.


Journal

European journal of cancer (Oxford, England : 1990)
ISSN: 1879-0852
Titre abrégé: Eur J Cancer
Pays: England
ID NLM: 9005373

Informations de publication

Date de publication:
03 2019
Historique:
received: 02 10 2018
revised: 27 12 2018
accepted: 28 12 2018
pubmed: 21 2 2019
medline: 16 5 2020
entrez: 21 2 2019
Statut: ppublish

Résumé

Although all tumours are rare in childhood, there are some particularly rare paediatric cancers which have not benefited from advances made by the international paediatric oncology network. To establish a shared definition and produce a list of these entities, the European Union Joint Action on Rare Cancers (JARC) promoted a consensus effort. The definition was based on the incidence rates estimated using the information network on rare cancers (RARECAREnet) database, pooling data from 94 population-based cancer registries and 27 countries. The RARECAREnet list of cancers was used to estimate the incidence rates. This list groups cancers by combining the International Classification of Diseases for Oncology, third edition, morphology and topography codes. According to the consensus, very rare paediatric cancers were identified as those with an annual incidence <2/1000000 and corresponded to 11% of all cancers in patients aged 0-14 years. Two subgroups were identified: tumour types typical of childhood (i.e. hepatoblastoma, pleuropulmonary blastoma, pancreatoblastoma) and those typical of adult age (i.e. carcinomas, melanoma). The threshold of 2/1000000 could also be adopted in populations aged 0-19 years: in this case, three tumour types had an incidence rate which was >2/1000000 (i.e. thyroid and testicular cancers and skin melanoma), but the consensus experts considered them as 'very rare' according to their clinical needs (e.g. shortage of knowledge and clinical expertise as the other rare paediatric cancers). The JARC consensus produced a definition and a list of very rare paediatric cancers which may represent a starting point for prioritising research on these tumours, based on data and patients' clinical needs.

Identifiants

pubmed: 30785015
pii: S0959-8049(19)30009-7
doi: 10.1016/j.ejca.2018.12.031
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

120-126

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Andrea Ferrari (A)

Paediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy.

Ines B Brecht (IB)

Paediatric Hematology and Oncology, Children's Hospital, Eberhard-Karls-Universitaet Tuebingen, Germany.

Gemma Gatta (G)

Department of Epidemiological Research and Molecular Medicine, Evaluative Epidemiology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy.

Dominik T Schneider (DT)

Paediatrics Clinic, Dortmund Municipal Hospital, Germany.

Daniel Orbach (D)

SIREDO Oncology Center (Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer), Institut Curie, PSL University, Paris, France.

Giovanni Cecchetto (G)

Paediatric Surgery, Department of Paediatrics, Padova University Hospital, Italy.

Jan Godzinski (J)

Department of Paediatric Surgery, Marciniak Hospital, Wroclaw, Poland.

Yves Reguerre (Y)

Paediatric Hematology-Oncology Department, Centre Hospitalier Universitaire, Saint Denis de La Réunion, France.

Ewa Bien (E)

Department of Paediatrics, Hematology and Oncology, Medical University, Gdansk, Poland.

Teresa Stachowicz-Stencel (T)

Department of Paediatrics, Hematology and Oncology, Medical University, Gdansk, Poland.

Michael Ost (M)

Paediatric Hematology and Oncology, Children's Hospital, Eberhard-Karls-Universitaet Tuebingen, Germany.

Chiara Magni (C)

Paediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy.

Pamela Kearns (P)

Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK; European Society for Paediatric Oncology (SIOPE Europe).

Gilles Vassal (G)

European Society for Paediatric Oncology (SIOPE Europe); Department of Clinical Research, Gustave Roussy, Paris-Sud University, Paris, France.

Maura Massimino (M)

Paediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy.

Andrea Biondi (A)

Department of Paediatrics, University of Milano-Bicocca, Fondazione MBBM/Ospedale San Gerardo, Monza, Italy.

Gianni Bisogno (G)

Hematology-Oncology Division, Department of Women's and Children's Health, Padova University Hospital, Italy.

Annalisa Trama (A)

Department of Epidemiological Research and Molecular Medicine, Evaluative Epidemiology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy. Electronic address: annalisa.trama@istitutotumori.mi.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH